Impact of Respiratory Bacterial Findings on Patients with Chronic Pulmonary Aspergillosis
Table 6
Comparison of clinical characteristics with and without Klebsiella spp. in sputum or bronchial washing fluid among study participants (N = 142).
Klebsiella spp.
value
Yes
No
(n = 35)
(n = 107)
Age (years)
67 (62–75)
66 (59–74)
0.337
Sex (male)
26 (74.3)
68 (63.6)
0.305
Body mass index (kg/m2)
20.8 (16.4–23.0)
19.4 (17.3–21.8)
0.567
Underlying lung disease
Previous history of pulmonary tuberculosis
26 (74.3)
71 (66.4)
0.412
Nontuberculous mycobacterial pulmonary disease
13 (37.1)
35 (32.7)
0.683
Bronchiectasis
11 (31.4)
35 (32.7)
>0.999
Emphysema
9 (25.7)
36 (33.6)
0.412
Interstitial lung disease
3 (8.6)
6 (5.6)
0.689
Previous history of thoracic malignancy
1 (2.9)
7 (6.5)
0.679
Other comorbidities
Diabetes mellitus
12 (34.3)
23 (21.5)
0.174
Congestive heart disease
2 (5.7)
9 (8.4)
>0.999
Chronic hepatic insufficiency
3 (8.6)
6 (5.6)
0.689
Chronic renal insufficiency
2 (5.7)
5 (4.7)
>0.999
Rheumatic disease
1 (2.9)
8 (7.5)
0.452
Previous history of extrathoracic malignancy
3 (8.6)
6 (5.6)
0.689
Chronic pulmonary symptoms
Cough
16 (45.7)
46 (43.0)
0.845
Sputum
17 (48.6)
57 (53.3)
0.698
Breathlessness†
11 (31.4)
46 (43.0)
0.241
Hemoptysis
17 (48.6)
40 (37.4)
0.321
Chest computed tomographic findings
Cavitation
35 (100)
107 (100)
NA
Paracavitary infiltrates
32 (91.4)
101 (94.4)
0.689
Mycetoma
12 (34.3)
29 (27.1)
0.519
Consolidation
2 (5.7)
10 (9.3)
0.730
Bilateral pulmonary lesions
10 (28.6)
27 (25.2)
0.825
Laboratory findings
White blood cells (μL)
7,520 (5,750−9,920)
7,960 (6,030−9,945)
0.815
C-reactive protein (mg/L)
15.7 (3.1–30.8)
10.4 (2.1–36.7)
0.759
Albumin (g/dL)
4.0 (3.5–4.3)
4.1 (3.7–4.4)
0.291
Data are presented as the median (interquartile range) or number (%). Cases are duplicated. †Breathlessness represents a modified Medical Research Council dyspnea score ≥ 2.
